Profile data is unavailable for this security.
About the company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
- Revenue in CHF (TTM)232.51m
- Net income in CHF-117.94m
- Incorporated2017
- Employees938.00
- LocationIdorsia LtdHegenheimermattweg 91ALLSCHWIL 4123SwitzerlandCHE
- Websitehttps://www.idorsia.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 71.72m | 41.83m | 575.48m | 193.00 | 18.99 | 6.91 | 12.64 | 8.02 | 1.14 | 1.14 | 1.96 | 3.13 | 0.5961 | 5.65 | 21.87 | 430,158.50 | 34.77 | 0.7964 | 40.11 | 0.8907 | 74.04 | 58.86 | 58.33 | 3.70 | 5.52 | -- | 0.0837 | -- | 219.91 | 42.46 | 835.14 | 100.38 | 10.46 | -- |
| Valneva SE | 163.92m | -93.08m | 680.63m | 700.00 | -- | 4.95 | -- | 4.15 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Basilea Pharmaceutica AG Allschwil | 236.21m | 72.66m | 759.26m | 180.00 | 10.89 | 6.79 | 10.18 | 3.21 | 5.23 | 5.23 | 17.03 | 8.40 | 1.08 | 1.66 | 10.57 | 1,440,305.00 | 33.21 | 7.08 | 39.78 | 11.18 | 81.04 | 82.50 | 30.76 | 9.96 | 5.67 | 31.61 | 0.4428 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Gubra A/S | 321.65m | 213.01m | 778.88m | 275.00 | -- | 5.25 | -- | 2.42 | -1.03 | -1.03 | 161.54 | 74.35 | 1.50 | -- | 68.31 | 11,174,780.00 | 99.21 | -- | 190.28 | -- | 3.52 | -- | 66.22 | -- | -- | -- | 0.0709 | -- | 29.63 | -- | 18.03 | -- | -- | -- |
| Nanobiotix SA | -12.80m | -47.05m | 917.22m | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Kuros Biosciences AG | 87.19m | -4.65m | 986.73m | 122.00 | -- | 16.22 | -- | 11.32 | -0.1218 | -0.1349 | 2.25 | 1.55 | 1.16 | 1.75 | 7.11 | 714,712.10 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Inventiva SA | 12.40m | -283.41m | 994.81m | 84.00 | -- | -- | -- | 80.22 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Idorsia Ltd | 232.51m | -117.94m | 997.22m | 938.00 | -- | -- | -- | 4.29 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Evotec SE | 689.08m | -144.84m | 1.00bn | 4.79k | -- | 1.37 | -- | 1.45 | -0.8955 | -0.8955 | 4.26 | 4.50 | 0.4019 | 20.15 | 5.17 | 156,687.00 | -8.45 | -2.40 | -10.41 | -2.87 | 10.82 | 21.49 | -21.02 | -6.78 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Oxford BioMedica plc | 158.44m | -38.84m | 1.04bn | 900.00 | -- | 26.69 | -- | 6.58 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
Data as of Feb 16 2026. Currency figures normalised to Idorsia Ltd's reporting currency: Swiss Franc CHF
16.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 12.57m | 5.01% |
| UBS Asset Management Switzerland AGas of 13 Dec 2025 | 7.74m | 3.09% |
| Astaris Capital Management LLPas of 26 Feb 2025 | 5.60m | 2.23% |
| LMR Partners LLPas of 26 Aug 2025 | 3.81m | 1.52% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 3.66m | 1.46% |
| D. E. Shaw & Co. LPas of 22 Jul 2025 | 3.55m | 1.42% |
| Rossier, Mari & Associates AGas of 30 Jun 2025 | 1.60m | 0.64% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.08m | 0.43% |
| Pictet Asset Management SAas of 31 Oct 2025 | 639.91k | 0.26% |
| BlackRock Asset Management Deutschland AGas of 05 Feb 2026 | 521.81k | 0.21% |
More ▼
Data from 30 Jun 2025 - 28 Jan 2026Source: FactSet Research Systems Inc.
